PT-141 Peptide Calculator

PT-141, designated Bremelanotide in clinical nomenclature, is a synthetic cyclic heptapeptide and a direct metabolite of Melanotan II (MT-II). It is generated in vivo when the C-terminal amide group of MT-II undergoes enzymatic hydrolysis, converting it to a carboxylic acid form. This metabolic relationship is pharmacologically significant: PT-141 inherits the melanocortin receptor agonism of MT-II but with a substantially altered receptor subtype selectivity profile—reduced MC1R affinity and enriched activity at MC3R and MC4R. Its molecular formula is C₅₀H₆₈N₁₄O₁₀ with a molecular weight of 1,025.2 Da.

As a non-selective melanocortin receptor agonist acting predominantly at MC3R and MC4R, PT-141 activates central nervous system pathways governing sexual arousal and motivation—a mechanism entirely distinct from peripheral vascular agents such as PDE5 inhibitors. This CNS-mediated mode of action has made it the subject of sustained preclinical interest and, ultimately, the first approved melanocortin-based therapeutic (FDA approval, 2019, for hypoactive sexual desire disorder in premenopausal women).

Melanocortin Receptor Agonist — Not a PDE5 Inhibitor

Conventional erectogenic research compounds target the peripheral vascular system: PDE5 inhibitors block phosphodiesterase type 5 in penile smooth muscle, potentiating cGMP-mediated vasodilation driven by nitric oxide (NO) release during sexual stimulation. PT-141 operates through an entirely orthogonal mechanism. It does not interact with the NO/cGMP axis, does not require concurrent sexual stimulation as a prerequisite for activity, and produces no clinically significant vasodilatory effect. Instead, it acts centrally—upstream of the vascular response—by activating melanocortin receptors in the brain to initiate the neural signaling cascade that drives sexual arousal at the level of motivation and desire, not merely vascular mechanics.

Hypothalamic MC4R and the Erectogenic Neural Pathway

MC4R is expressed at high density in the paraventricular nucleus (PVN) of the hypothalamus—a critical integration hub for autonomic, neuroendocrine, and behavioral output. PT-141 binding at hypothalamic MC4R activates Gαs-coupled signaling (adenylyl cyclase → cAMP → PKA), which drives oxytocinergic neurons in the PVN to release oxytocin into both systemic circulation and, via axonal projections, into limbic structures including the medial preoptic area (MPOA). This oxytocin-mediated pathway modulates dopaminergic reward circuitry and activates descending spinal neural pathways that coordinate the erectogenic reflex arc—producing erection in male rodent models through a mechanism independent of peripheral vascular tone. The MPOA is a particularly important node: lesion studies in rodents demonstrate that MPOA integrity is required for PT-141's behavioral effects, confirming the centrally-mediated mechanism.

MC3R: The Modulatory Co-Receptor

MC3R, expressed in hypothalamic feeding centers and limbic regions, functions in part as an autoreceptor modulating melanocortinergic tone. PT-141's agonism at MC3R is thought to contribute to appetite suppression and energy homeostasis modulation observed in some research models. In the context of sexual arousal research, MC3R activation may play a facilitatory role by attenuating the inhibitory melanocortinergic autoreceptor brake, amplifying the net MC4R-driven arousal response. Dissecting MC3R vs. MC4R contributions remains an active area of preclinical investigation using receptor-selective analogs and conditional knockout models.

Standard Research Vial and the Case for 2ml Diluent

PT-141 is most commonly supplied in 10mg lyophilized vials for research use. Diluent volume selection is a precision-critical decision: too little BAC water produces a highly concentrated solution where each graduation on a standard insulin syringe carries a large dose increment, amplifying measurement error; too much diluent places the target dose near syringe capacity, compressing the error margin differently. For the 10mg vial, 2ml of bacteriostatic water represents the preferred diluent volume—yielding a concentration of 50 mcg per unit that places the commonly referenced 1.75mg research dose at a reproducible, mid-syringe draw of 35 units. A 2.5ml alternative (40 mcg/unit) is used when researchers prefer a slightly lower concentration with a wider dose-interpolation margin.

Step-by-Step Reconstitution Math

The PT-141 calculator uses the following formula to determine concentration and draw volume:

• 10mg vial + 2ml BAC water: 50 mcg/unit → 1.75mg (1,750mcg) = 35 units
• 10mg vial + 2ml BAC water: 50 mcg/unit → 1mg (1,000mcg) = 20 units
• 10mg vial + 2ml BAC water: 50 mcg/unit → 500mcg = 10 units
• 10mg vial + 2.5ml BAC water: 40 mcg/unit → 1.75mg (1,750mcg) ≈ 44 units
• Use the PT-141 calculator above to generate exact values for any vial size, diluent volume, or target dose.

Why 2ml Is the Preferred Diluent Volume

At 50 mcg/unit, the 2ml reconstitution maps the 1.75mg research dose to exactly 35 units—a draw that falls at 35% of syringe capacity, well within the high-precision measurement zone of a standard 100-unit insulin syringe (typically ±1 unit error = ±50mcg, or ±2.9% at this dose). Using 1ml BAC water doubles the concentration to 100 mcg/unit, placing 1.75mg at only 17.5 units—a draw that falls between syringe graduation marks and doubles the per-graduation dose increment. Using 5ml drops concentration to 20 mcg/unit, requiring 87.5 units for 1.75mg—approaching the syringe's physical maximum and eliminating buffer room for dose escalation within a single draw. The 2ml volume is the precision optimum for this vial size.

Onset Window

PT-141's CNS-mediated mechanism produces a distinct pharmacodynamic time profile. In rodent models, measurable behavioral effects emerge within 30–60 minutes of subcutaneous administration, reaching peak activity at approximately 1–2 hours post-dose. In the clinical trial data for Bremelanotide, peak plasma concentration (Tmax) is reached in approximately 1 hour following subcutaneous administration, with behavioral and subjective arousal effects reported most intensely across the 2–6 hour post-dose window. This characteristic lag between plasma Cmax and peak behavioral effect reflects the time required for CNS receptor occupancy to propagate through the oxytocinergic and dopaminergic circuits downstream of MC4R activation.

Half-Life and Washout Timing

PT-141 has a terminal plasma half-life of approximately 2.7 hours, with total behavioral effects resolving within 12 hours in most rodent study designs. For preclinical assay planning this means: (1) behavioral assessment windows should be standardized within the 1–6 hour post-dose period for peak-effect capture; (2) washout periods between research sessions should be a minimum of 24–48 hours for full systemic clearance; and (3) repeated-dose receptor desensitization at MC4R may attenuate response with high-frequency administration—spacing sessions ≥72 hours apart is advisable to maintain between-session reproducibility and avoid tachyphylaxis confounding longitudinal dose-response analysis.

PT-141 contains a disulfide bridge between Cys⁴ and Cys¹⁰ that locks the peptide into the cyclic conformation required for melanocortin receptor binding. Loss of this disulfide—via reduction, oxidation to sulfonic acid, or photolytic cleavage—converts the peptide to an inactive linear form without producing any visible change in solution appearance. This makes visual inspection an unreliable potency indicator after a storage breach.

• Lyophilized at room temperature (20–25°C): Acceptable for short-term storage and transit (up to 4–6 weeks) when desiccated and protected from humidity and light. Prefer cold storage for any protocol requiring documented potency over multi-month timelines.
• Lyophilized at 2°C–8°C (refrigerated): Recommended working stock. Stable for 6–12 months with desiccation and light protection.
• Lyophilized at −20°C (long-term): Optimal. Stable for 24 months or longer. Desiccate and seal vials before freezing; moisture ingress during freeze-thaw cycles is a primary degradation driver.
• Reconstituted at 2°C–8°C: Mandatory. Use within 28–30 days. Temperatures above 25°C accelerate both disulfide bond reduction and peptide backbone hydrolysis in the reconstituted state.
• Never freeze reconstituted solution: Ice crystal formation mechanically disrupts the cyclic peptide conformation and can cleave the disulfide bridge. Discard any reconstituted vial accidentally frozen.
• Light protection: The disulfide bridge undergoes photolytic cleavage under direct UV exposure. Store in amber vials or foil-wrapped vials at all stages. Limit bench-top exposure during preparation.

Does PT-141 cause tanning like Melanotan II in research models?

Melanotan II stimulates robust melanogenesis because it is a potent agonist at MC1R on melanocytes—the receptor subtype directly responsible for eumelanin synthesis and UV-independent skin darkening. PT-141's receptor selectivity profile is weighted toward MC3R and MC4R, and its binding affinity for MC1R is significantly lower than MT-II at the concentrations typically employed in arousal research. In practice, melanogenic effects with PT-141 are substantially reduced compared to equimolar MT-II. However, MC1R agonism is not absent: at higher doses or in subjects with constitutively high baseline MC1R expression, modest pigmentary changes including mild transient skin darkening and increased freckling have appeared in clinical trial data. In preclinical rodent models, where fur pigmentation serves as a visible MC1R activation proxy, PT-141 produces markedly less darkening than MT-II at equivalent doses. Researchers designing pigmentation-controlled behavioral studies should include selective MC1R antagonists as controls if excluding this confound is required for outcome validity.

Why is nausea commonly reported in PT-141 research?

Nausea is the most frequently reported adverse effect in PT-141 clinical trials and the primary dose-limiting tolerability concern. The mechanistic basis is MC4R activation in the area postrema (AP) and nucleus tractus solitarius (NTS) of the brainstem—regions that constitute the chemoreceptor trigger zone (CTZ) and integrate emetic reflex signaling. Because these circumventricular brainstem structures have a fenestrated blood-brain barrier, they are accessible to circulating PT-141, meaning the same receptor population that drives the hypothalamic arousal response also activates the brainstem emetic circuit. This is an on-target, mechanism-based adverse effect—not a formulation artifact. In preclinical models, the nausea response is dose-dependent and diminishes with repeated administration, suggesting MC4R tachyphylaxis at brainstem level. Researchers modeling PT-141 tolerability should quantify nausea-associated behaviors (pica, kaolin intake in rodents) as a parallel endpoint to the primary arousal outcome to provide complete dose-tolerability characterization at each experimental level.